{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.50","value":"-54.14"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.62","value":"-64.04"}]}],"title":"9 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Mean percent change in parathyroid hormone (PTH) levels will be calculated.","dispersionType":"Standard Error","groups":[{"description":"Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.\n\nEtelcalcetide: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.","id":"OG000","title":"Study Participant"}],"paramType":"MEAN","populationDescription":"Only includes participants who completed the study","reportingStatus":"POSTED","timeFrame":"Baseline and 9 months","title":"Percent Change in PTH Levels","type":"PRIMARY","unitOfMeasure":"percentage of change in PTH levels"}